Chaperone-mediated autophagy as a modulator of aging and longevity

Chaperone-mediated autophagy (CMA) is the lysosomal degradation of individually selected proteins, independent of vesicle fusion. CMA is a central part of the proteostasis network in vertebrate cells. However, CMA is also a negative regulator of anabolism, and it degrades enzymes required for glycol...

Full description

Saved in:
Bibliographic Details
Main Author: S. Joseph Endicott
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Aging
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fragi.2024.1509400/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850059675796504576
author S. Joseph Endicott
S. Joseph Endicott
author_facet S. Joseph Endicott
S. Joseph Endicott
author_sort S. Joseph Endicott
collection DOAJ
description Chaperone-mediated autophagy (CMA) is the lysosomal degradation of individually selected proteins, independent of vesicle fusion. CMA is a central part of the proteostasis network in vertebrate cells. However, CMA is also a negative regulator of anabolism, and it degrades enzymes required for glycolysis, de novo lipogenesis, and translation at the cytoplasmic ribosome. Recently, CMA has gained attention as a possible modulator of rodent aging. Two mechanistic models have been proposed to explain the relationship between CMA and aging in mice. Both of these models are backed by experimental data, and they are not mutually exclusionary. Model 1, the “Longevity Model,” states that lifespan-extending interventions that decrease signaling through the INS/IGF1 signaling axis also increase CMA, which degrades (and thereby reduces the abundance of) several proteins that negatively regulate vertebrate lifespan, such as MYC, NLRP3, ACLY, and ACSS2. Therefore, enhanced CMA, in early and midlife, is hypothesized to slow the aging process. Model 2, the “Aging Model,” states that changes in lysosomal membrane dynamics with age lead to age-related losses in the essential CMA component LAMP2A, which in turn reduces CMA, contributes to age-related proteostasis collapse, and leads to overaccumulation of proteins that contribute to age-related diseases, such as Alzheimer’s disease, Parkinson’s disease, cancer, atherosclerosis, and sterile inflammation. The objective of this review paper is to comprehensively describe the data in support of both of these explanatory models, and to discuss the strengths and limitations of each.
format Article
id doaj-art-cc05c073e48e4c719f7640aa08575572
institution DOAJ
issn 2673-6217
language English
publishDate 2024-12-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Aging
spelling doaj-art-cc05c073e48e4c719f7640aa085755722025-08-20T02:50:49ZengFrontiers Media S.A.Frontiers in Aging2673-62172024-12-01510.3389/fragi.2024.15094001509400Chaperone-mediated autophagy as a modulator of aging and longevityS. Joseph Endicott0S. Joseph Endicott1Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM, United StatesAutophagy, Inflammation, and Metabolism Center of Biomedical Research Excellence, (AIM CoBRE), University of New Mexico Health Sciences Center, Albuquerque, NM, United StatesChaperone-mediated autophagy (CMA) is the lysosomal degradation of individually selected proteins, independent of vesicle fusion. CMA is a central part of the proteostasis network in vertebrate cells. However, CMA is also a negative regulator of anabolism, and it degrades enzymes required for glycolysis, de novo lipogenesis, and translation at the cytoplasmic ribosome. Recently, CMA has gained attention as a possible modulator of rodent aging. Two mechanistic models have been proposed to explain the relationship between CMA and aging in mice. Both of these models are backed by experimental data, and they are not mutually exclusionary. Model 1, the “Longevity Model,” states that lifespan-extending interventions that decrease signaling through the INS/IGF1 signaling axis also increase CMA, which degrades (and thereby reduces the abundance of) several proteins that negatively regulate vertebrate lifespan, such as MYC, NLRP3, ACLY, and ACSS2. Therefore, enhanced CMA, in early and midlife, is hypothesized to slow the aging process. Model 2, the “Aging Model,” states that changes in lysosomal membrane dynamics with age lead to age-related losses in the essential CMA component LAMP2A, which in turn reduces CMA, contributes to age-related proteostasis collapse, and leads to overaccumulation of proteins that contribute to age-related diseases, such as Alzheimer’s disease, Parkinson’s disease, cancer, atherosclerosis, and sterile inflammation. The objective of this review paper is to comprehensively describe the data in support of both of these explanatory models, and to discuss the strengths and limitations of each.https://www.frontiersin.org/articles/10.3389/fragi.2024.1509400/fullagingautophagychaperone-mediated autophagylongevitymetabolism
spellingShingle S. Joseph Endicott
S. Joseph Endicott
Chaperone-mediated autophagy as a modulator of aging and longevity
Frontiers in Aging
aging
autophagy
chaperone-mediated autophagy
longevity
metabolism
title Chaperone-mediated autophagy as a modulator of aging and longevity
title_full Chaperone-mediated autophagy as a modulator of aging and longevity
title_fullStr Chaperone-mediated autophagy as a modulator of aging and longevity
title_full_unstemmed Chaperone-mediated autophagy as a modulator of aging and longevity
title_short Chaperone-mediated autophagy as a modulator of aging and longevity
title_sort chaperone mediated autophagy as a modulator of aging and longevity
topic aging
autophagy
chaperone-mediated autophagy
longevity
metabolism
url https://www.frontiersin.org/articles/10.3389/fragi.2024.1509400/full
work_keys_str_mv AT sjosephendicott chaperonemediatedautophagyasamodulatorofagingandlongevity
AT sjosephendicott chaperonemediatedautophagyasamodulatorofagingandlongevity